Medtronic (MDT) Cash from Financing Activities (2014 - 2026)

Medtronic (MDT) has 13 years of Cash from Financing Activities data on file, last reported at -$888.0 million in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities rose 33.88% year-over-year to -$888.0 million; the trailing twelve-month figure through Apr 2026 stood at -$4.8 billion (down 8.94% YoY), and the FY2026 full-year result was -$4.8 billion, down 8.94% from the prior year.
• Cash from Financing Activities climbed to -$888.0 million in Q2 2026, from -$2.1 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.0 billion in Q4 2022 to a low of -$4.9 billion in Q2 2023.
• A 5-year average of -$1.2 billion and a median of -$1.3 billion in 2022 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 360.95% in 2022 and sank 493.33% in 2024, its largest moves.
• Tracing MDT's Cash from Financing Activities over 5 years: stood at $3.0 billion in 2022, then slumped by 102.99% to -$90.0 million in 2023, then slumped by 493.33% to -$534.0 million in 2024, then gained by 26.03% to -$395.0 million in 2025, then plunged by 124.81% to -$888.0 million in 2026.
• Business Quant data shows MDT's Cash from Financing Activities at -$888.0 million in Q2 2026, -$2.1 billion in Q1 2026, and -$395.0 million in Q4 2025.